Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

NCT04128748 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Blasts More Than 10 Percent of Bone Marrow Nucleated Cells
High Risk Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome

Interventions

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine
DRUG: Quizartinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]